Philip Wexler, MD
Pulmonary Disease · Atlanta, GANPI 1932175700
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 56 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 22.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $604 and has fallen 93.6% since, to $38 in 2023. That places this record below the midpoint for pulmonary disease clinicians in GA, where the typical reported total is $3,789.
Across 56 payments — averaging $15.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mylan Specialty L.p.$194
- GSK$127
- Sunovion Pharmaceuticals Inc.$80
- Genentech USA, Inc.$63
- Regeneron Healthcare Solutions, Inc.$57
- Boehringer Ingelheim$48
- plus $306 from 13 others
Across 30 payments — averaging $4383.08 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astrazeneca AB$55K
- Mallinckrodt Enterprises LLC$25K
- AstraZeneca$21K
- Mallinckrodt Hospital Products Inc.$17K
- Sanofi US Services Inc.$13K
What the payments were for
- Food & beverage$86699%
- Education$81%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mylan Specialty L.p. | 9 | $194 |
| GSK | 12 | $127 |
| Sunovion Pharmaceuticals Inc. | 5 | $80 |
| Genentech USA, Inc. | 4 | $63 |
| Regeneron Healthcare Solutions, Inc. | 3 | $57 |
| Boehringer Ingelheim | 3 | $48 |
| Sanofi | 2 | $44 |
| Shire North American Group Inc | 2 | $34 |
| Actelion Pharmaceuticals US, Inc. | 2 | $33 |
| Vyaire Medical, Inc. | 2 | $32 |
| Insmed, Inc. | 2 | $31 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $30 |
| Advanced Respiratory, Inc | 1 | $24 |
| AbbVie | 1 | $20 |
| Kaleo, Inc. | 1 | $15 |
| Johnson & Johnson | 1 | $13 |
| Pfizer | 1 | $11 |
| AstraZeneca | 1 | $11 |
| United Therapeutics Corporation | 3 | $8 |
How this compares
$874 in reported general payments places this provider in the 25th percentile of 365 pulmonary disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Atlanta
- Colin SwensonAtlanta$255K
- Eric FlenaughAtlanta$93K
- Gregory MartinAtlanta$88K
- Victor TsengAtlanta$55K
- Ralitza MartinAtlanta$48K
- Venkatesh LakshminarayananAtlanta$33K
- Sisir AkkineniAtlanta$21K
- Gerald StatonAtlanta$21K
- Mirza AliAtlanta$16K
- Srihari VeeraraghavanAtlanta$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.